FHC
NAGE

First Horizon Corporation’s Niagen Bioscience NAGE Stock Holding History

First Horizon Corporation’s Portfolio NAGE Stock Details NAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		$0 Hold
37
– – ﹤0.01% 1240
2021
Q1 		$0 Hold
37
– – ﹤0.01% 1241
2020
Q4 		$0 Hold
37
– – ﹤0.01% 1255
2020
Q3 		$0 Buy
+37
New +$178 ﹤0.01% 1187

Other funds holding NAGE

YRHAM
Yong Rong (HK) Asset Management Sheung Wan, Hong Kong $227M AUM 300.38% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
UIC
Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

First Horizon Corporation's NAGE Position: Q2 2021 in Review

First Horizon Corporation held its Niagen Bioscience (NAGE) position steady in Q2 2021 at 37 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #1240.

First Horizon Corporation first reported a position in NAGE in Q3 2020 and has held it in 4 quarters since. 101 funds tracked by Wall St. Rank hold NAGE as of Q2 2021.

  • First Horizon Corporation held 37 shares of Niagen Bioscience worth $0 as of Q2 2021.
  • First Horizon Corporation left its Niagen Bioscience share count unchanged in Q2 2021.
  • Niagen Bioscience made up ﹤0.01% of First Horizon Corporation's portfolio in Q2 2021, its #1240 holding.
  • First Horizon Corporation first reported a position in Niagen Bioscience in Q3 2020 and has held it in 4 quarters since.
  • 101 funds tracked by Wall St. Rank held Niagen Bioscience as of Q2 2021.

Based on First Horizon Corporation's 13F filing for Q2 2021, filed 9 Aug 2021.